ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.261,75
-0,22%
S&P 500
5.998,74
-0,38%
Dow Jones
44.722,06
-0,31%
Euro vs US Dollar
1,05565
-0,06%
Bitcoin
95.531,02
-0,47%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Avadel Pharmaceuticals PLC (AVDL)

  7. Avadel Pharmaceuticals PLC (AVDL) News

AVDL

Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AVDL
DatumZeitQuelleÜberschriftSymbolFirma
14/11/202417h50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
14/11/202412h10Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
13/11/202423h58Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
13/11/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/11/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/11/202413h00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
04/11/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/10/202412h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
31/10/202412h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act LitigationNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202420h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep AdvancesNASDAQ:AVDLAvadel Pharmaceuticals PLC
17/10/202416h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
17/10/202415h41GlobeNewswire Inc.Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with NarcolepsyNASDAQ:AVDLAvadel Pharmaceuticals PLC
25/09/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting AgentNASDAQ:AVDLAvadel Pharmaceuticals PLC
16/09/202423h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
14/09/202400h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/09/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/09/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
03/09/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)NASDAQ:AVDLAvadel Pharmaceuticals PLC
28/08/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:AVDLAvadel Pharmaceuticals PLC
28/08/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
20/08/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral SuspensionNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202415h25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202413h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202413h00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202422h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202422h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202422h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:AVDL

Kürzlich von Ihnen besucht

NYSE
RCI
Rogers Communications
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten

BLACK FRIDAY

ADVFN

Seit 25 Jahren im Geschäft 1999-2024

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

*Über 3 Jahre 1094.04€, jetzt nur noch 437.62€